Brendan Hannah - 23 Jan 2026 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Reporting relationship: CBO, COO & CCO
Issuer ticker: QNCX
Reported as of: 23 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 20:05:44 UTC
Prior SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Brendan Hannah

Key filing fact

Brendan Hannah filed Form 4 for Quince Therapeutics, Inc. (QNCX) on 23 Jan 2026.

Key facts

This page summarizes Brendan Hannah's Form 4 filing for Quince Therapeutics, Inc. (QNCX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2026, 20:05.

Change

Previous filing in this sequence was filed on 08 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001929422 Primary reporting owner

Hannah Brendan

Relationship: CBO, COO & CCO
Address: C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Signature: /s/ Brendan Hannah
Signature date: 23 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: -365,000
Change %: -50%
Price: $0.000000
Shares after: 365,000
Date: 23 Jan 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 365,000
Exercise price: $3.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.